BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21235699)

  • 1. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    Lord R; Suddle A; Ross PJ
    Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced HCC: emerging molecular therapies.
    Finn RS
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):25-34. PubMed ID: 22419002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy of hepatocellular carcinoma: are we making progress?
    Roxburgh P; Evans TR
    Adv Ther; 2008 Nov; 25(11):1089-104. PubMed ID: 18972075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S; Bouattour M; Raymond E
    Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY; Park JW
    Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
    Witjes CD; Verhoef C; Verheul HM; Eskens FA
    Neth J Med; 2009 Mar; 67(3):86-90. PubMed ID: 19307678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established and emerging therapies for hepatocellular carcinoma.
    Cicinnati VR; Sotiropoulos GC; Beckebaum S
    Minerva Med; 2010 Dec; 101(6):405-18. PubMed ID: 21196900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
    Gish RG; Abou-Alfa GK; Tong MJ
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):2 p preceding 4-15. PubMed ID: 21598749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT; Frederick RT; Gish RG
    J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling pathways in hepatocellular carcinoma.
    Sia D; Villanueva A
    Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the treatment response of HCC.
    Kim KW; Lee JM; Choi BI
    Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeting for treatment of advanced hepatocellular carcinoma.
    Song IH
    Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of hepatocellular carcinoma and molecular therapies.
    Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
    Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.